Manuel Ramón García-Sáenz

Dr. Manuel Ramón García-Sáenz

Mexican Social Security Institute, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
RIRaúl Ibarra-Salce
Raúl Ibarra-Salce
FPFrancisco Javier Pozos-Varela
Francisco Javier Pozos-Varela
TMTania Sofia Mena-Ureta
Tania Sofia Mena-Ureta
SFSusana Flores
Susana Flores
Aldo Ferreira-HermosilloAldo Ferreira-Hermosillo
Aldo Ferreira-Hermosillo
Progestin is a term used to describe a synthetic progestogen. The activity and potency of synthetic progestins are mostly evaluated via parameters associated with their endometrial effects, which are related to their interactions with progesterone, estrogen, androgen, glucocorticoid, and mineralocorticoid receptors. The chemical structure of progestins is the key to understanding their interactions with these receptors and predicting the other effects associated with these drugs. Due to their endometrial effect, progestins are used for different gynecological conditions, such as endometriosis, contraception, hormonal replacement therapy, and artificial reproduction techniques. This review is focused on improving our knowledge of progestins (from their history and biochemical effects related to their chemical structures to clinical applications in gynecological conditions) in order to improve clinical practice.

2 April 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
MSMiriam Sánchez-García
Miriam Sánchez-García
KLKapy Leon-Wu
Kapy Leon-Wu
RIRegina de Miguel Ibañez
Regina de Miguel Ibañez
NLNitzia López-Juárez
Nitzia López-Juárez
Claudia Ramirez-RenteriaClaudia Ramirez-Renteria
Claudia Ramirez-Renteria
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
Background: Estrogen plays a crucial role in adipose tissue homeostasis, influencing fat distribution, lipid metabolism, and insulin sensitivity. Through estrogen receptor (ER) activation, particularly ERα, estradiol (E2) regulates adipogenesis, inhibits adipocyte hypertrophy, and promotes insulin signaling. It enhances lipid oxidation, reduces lipogenesis, and suppresses pro-inflammatory cytokine production, thereby maintaining metabolic health. Primary ovarian insufficiency (POI), characterized by estrogen deficiency before the age of 40, disrupts this regulatory network, leading to adverse metabolic effects. Objetives: This review examines the effects of estrogen on adipose tissue, lipid metabolism, and carbohydrate metabolism, with a particular focus on clinical evidence in women with POI. Methods: A narrative review of the metabolic alterations associated with POI, emphasizing the molecular, biochemical, and metabolic mechanisms underlying estrogen deficiency, with a special focus on adipose tissue. Results: Women with POI exhibit increased visceral fat accumulation, reduced lean mass, and alterations in adipokine secretion, resembling the metabolic phenotype of postmenopausal women. The decline in estrogen levels contributes to central adiposity, impaired lipid metabolism, and insulin resistance, exacerbating the risk of type 2 diabetes (T2D) and cardiovascular disease (CVD). The loss of estrogenic regulation leads to enhanced lipolysis in visceral fat, raising free fatty acid flux to the liver, promoting hepatic steatosis, and worsening insulin resistance. Studies indicate that POI patients have significantly higher total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides compared to age-matched controls, reinforcing their heightened CVD risk. Reduced sex hormone-binding globulin (SHBG) levels increase free androgen availability, aggravating central fat deposition. These metabolic disturbances can potentially accelerate atherosclerosis and vascular aging, increasing morbidity and mortality in POI patients. Conclusions: Understanding the role of estrogen in adipose tissue and its disruption in POI highlights the importance of early intervention. Although the available evidence is limited and largely extrapolated from menopause studies, strategies such as hormone replacement therapy, lifestyle modifications, and lipid profile optimization are essential to mitigate metabolic consequences and improve long-term health outcomes in women with POI.

14 April 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
MLMiry Lobaton
Miry Lobaton
Aldo Ferreira-HermosilloAldo Ferreira-Hermosillo
Aldo Ferreira-Hermosillo
Metformin is a synthetic biguanide that improves insulin sensitivity and reduces hepatic gluconeogenesis. Aside being the first-line therapy for Type 2 Diabetes (T2D), many pleiotropic effects have been discovered in recent years, such as its capacity to reduce cancer risk and tumorigenesis. Although widely studied, the effect of metformin on thyroid cancer remains controversial. Potential mechanisms for its growth inhibitory effects have been elucidated in various preclinical studies that involved pathways related to adenosine mono-phosphate-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), mitochondrial glycerophosphate dehydrogenase (mGPDH), and the nuclear factor κB (NF-κB). Hyperinsulinemia increases cell glucose uptake and oxidative stress, and promotes thyroid cell growth, leading to hyperproliferation, carcinogenesis, and the development of malignant tumors. Furthermore, it has also been related to thyroid nodules size in nodular disease, as well as tumoral size in patients with thyroid cancer. Several clinical studies concluded that metformin might have an important role as an adjuvant therapy to reduce the growth of benign and malignant thyroid neoplasms. This suggests that metformin might be useful for patients with differentiated or poorly differentiated thyroid cancer and metabolic diseases such as insulin resistance or diabetes.

20 October 2023 in Archives of Medical Research
Verified
Journal Article
Closed access
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
MLMiry Lobaton
Miry Lobaton
Claudia Ramirez-RenteriaClaudia Ramirez-Renteria
Claudia Ramirez-Renteria
NLNitzia López-Juárez
Nitzia López-Juárez
Renata SaucedoRenata Saucedo
Renata Saucedo
Aldo Ferreira-HermosilloAldo Ferreira-Hermosillo
Aldo Ferreira-Hermosillo

31 August 2022
Verified
Journal Article
Open access
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
Aldo Ferreira-HermosilloAldo Ferreira-Hermosillo
Aldo Ferreira-Hermosillo
MLMiry Lobaton
Miry Lobaton
Diferentes citocinas proinflamatorias producidas durante la foliculogénesis tienen un rol fisiológico en el debilitamiento de la pared del folículo y la eventual ruptura en la ovulación. La inflamación crónica está relacionada de forma muy cercana con disfunción endotelial, enfermedad cardiovascular, enfermedad arterial coronaria y con el síndrome de ovario poliquístico. El síndrome de ovario poliquístico se caracteriza por un exceso de andrógenos y disfunción ovárica. Evidencia emergente sugiere que los efectos metabólicos a largo plazo y las complicaciones cardiovasculares observadas en este síndrome pueden estar relacionadas con la presencia de un estado inflamatorio crónico leve. Es poco claro si el exceso de andrógenos promueve un estado inflamatorio o, contrariamente, si las moléculas inflamatorias estimulan la producción de andrógenos. La detección temprana de los factores de riesgo ayudará en la prevención y el control de las enfermedades cardiovasculares, dado que las alteraciones metabólicas asociadas con este síndrome pueden predisponer a peores resultados de salud cardiovascular.

5 February 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
Laura Cristina Hernández-RamírezLaura Cristina Hernández-Ramírez
Laura Cristina Hernández-Ramírez
Claudia Ramirez-RenteriaClaudia Ramirez-Renteria
Claudia Ramirez-Renteria
RVRosa Gloria Rebollar Vega
Rosa Gloria Rebollar Vega
JZJulia M Zuarth-Vázquez
Julia M Zuarth-Vázquez
MTMariana Torres-Morán
Mariana Torres-Morán
LBLourdes Balcázar-Hernández
Lourdes Balcázar-Hernández
Context: Genetic tests are part of the routine clinical approach to syndromic and nonsyndromic phenotypes of neuroendocrine neoplasms (NENs). Current data on phenotype–genotype associations in NENs, however, do not accurately represent all populations. Objective: To describe the frequency, inventory, and clinical associations of germline defects associated with multiple types of NENs in a Mexican cohort. Methods: Blood DNA from Mexican adults with NENs was analyzed with a 53-gene next-generation sequencing panel developed ad hoc (n = 90) or Sanger sequencing (n = 2). Single nucleotide variants, indels, and structural variants were identified, classified, and subjected to orthogonal confirmation. When possible, tumor samples and blood DNA from additional family members were tested using Sanger sequencing. Results: Ninety-two probands (70.7% women, 51.5% sporadic) were included; 16 carried pathogenic or likely pathogenic (P/LP) variants and were significantly younger at disease onset than the rest (29.6 ± 10.7 vs 40 [21.5-51.5] years, P = .0384). Likely driving variants were identified in three-quarters of Von Hippel Lindau syndrome cases, one-third of multiple endocrine neoplasia (MEN) type 1, one-quarter of early-onset acromegaly/gigantism, and individual cases of Cushing's disease, MEN2A, and medullary thyroid carcinoma. One patient with clinical MEN1 associated with an SDHA variant and 1 with a pituitary tumor and neurofibromatosis type 1 were also identified. Probands with familial disease were more likely to carry P/LP variants than sporadic cases (26.7 vs 8.5%, P = .0282). Conclusion: P/LP variants were identified in 17.4% of individuals with NENs. Our research provides a view of the landscape of NEN drivers in a population not previously characterized.